Written especially for nurses caring for patients with cancer, the 2015 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Written especially for nurses caring for patients with cancer, the 2018 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

Written especially for nurses caring for patients with cancer, the 2017 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2017 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs. New drugs include: alectin

Like getting 7 books in 1, MOSBY'S ONCOLOGY NURSING ADVISOR provides quick access to essential information on a wide range of cancer topics, including types of cancer, treatment options, symptom management, palliative care, and patient teaching. Its user-friendly layout and straightforward coverage make it ideal for use in any clinical setting, offering authoritative guidance to help you provide the best possible oncology nursing care. Detailed descriptions of over 50 major cancer types provide essential information on incidence, etiology and risk factors, signs and symptoms, diagnostic workup, histology, staging, treatment, prognosis, and prevention. Coverage of cancer management principles outlines a wide range of treatment and pharmacologic modalities, including surgery, chemotherapy, radiation therapy, hormonal therapy, biological response modifiers, and complementary and alternative therapies. Symptom management guidelines provide in-depth coverage of pathophysiology, assessment tools, lab and diagnostic tests, differential diagnoses, interventions, follow up care, and resources for over 30 common symptoms associated with cancer and cancer treatments. Essential information on many oncologic emergencies and emergent issues prepares you to respond quickly to structural, metabolic, and hematologic emergencies. Helpful patient teaching resources include more than 25 reproducible patient teaching handouts. An entire section on palliative care and end-of-life issues offers helpful guidelines for dealing with topics related to hospice care, communication in palliative care, the final hours of the cancer patient, ethical considerations, and loss, grief, and bereavement. Serves as a great study tool for the oncology nursing certification exam..

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

This essential reference provides valuable information on effective symptom management and chemotherapy administration. The only oncology drug book that is updated every year.

2006 Oncology Nursing Drug Handbook is a comprehensive nursing resource for assessment, intervention, and patient education in the administration of oncology drugs. This text reviews drug information from the nurse's point of view, and helps the nurse focus on minimizing toxicity. This essential reference provides valuable information on effective symptom management and chemotherapy administration for the oncology nurse. Updated annually, the 2006 edition includes the following new drugs: four antineoplastic agents (clofarabine, histrelin implant, paclitaxel protein bound particles for injection, TLK 286), four antimicrobial agents (micafungin, rifaximin, gemifloxacin, tigecycline), two immunotherapy/biotherapy symptom management agents (Imiquimod 5% cream., palifermin), and eight molecularly targeted drugs (lapatanib, panitumumab, pertuzumab, sorafeni (BAY 43-9006), sunitinib malate (sutent, SU11246), temsirolimus, tipifarnib, vatalanib), and one symptom management drug (ziconotide intrathecal infusion). In addition, indications and additional toxicity data have been updated for individual drugs, such as bevacizumab, cetuximab, and gefitinib.